Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123269034 | 12326903 | 4 | F | 201506 | 20160629 | 20160503 | 20160705 | EXP | US-PFIZER INC-2016211193 | PFIZER | 73.00 | YR | F | Y | 87.90000 | KG | 20160705 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123269034 | 12326903 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 100 MG, 2X/DAY | 20235 | 100 | MG | CAPSULE, HARD | BID | ||||||
| 123269034 | 12326903 | 2 | SS | GABAPENTIN. | GABAPENTIN | 1 | 600 MG, 3X/DAY | 20235 | 600 | MG | CAPSULE, HARD | TID | |||||||
| 123269034 | 12326903 | 3 | SS | GABAPENTIN. | GABAPENTIN | 1 | 100 MG, 1X/DAY (AT NIGHT) | 16714-066102 | 20235 | 100 | MG | CAPSULE, HARD | QD | ||||||
| 123269034 | 12326903 | 4 | SS | GABAPENTIN. | GABAPENTIN | 1 | 600 MG, 2X/DAY | 20235 | 600 | MG | CAPSULE, HARD | BID | |||||||
| 123269034 | 12326903 | 5 | SS | GABAPENTIN. | GABAPENTIN | 1 | 300 MG, 2X/DAY | 20235 | 300 | MG | CAPSULE, HARD | BID | |||||||
| 123269034 | 12326903 | 6 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | 75 UG, 1X/DAY | 0 | 75 | UG | QD | ||||||||
| 123269034 | 12326903 | 7 | C | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | 100 MG, 1X/DAY | 0 | 100 | MG | QD | ||||||||
| 123269034 | 12326903 | 8 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 100 MG, 1X/DAY | 0 | 100 | MG | QD | ||||||||
| 123269034 | 12326903 | 9 | C | TEGRETOL | CARBAMAZEPINE | 1 | 100 MG (200 MG 1/2 TAB), AS NEEDED | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123269034 | 12326903 | 1 | Trigeminal neuralgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123269034 | 12326903 | OT |
| 123269034 | 12326903 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123269034 | 12326903 | Decreased appetite | |
| 123269034 | 12326903 | Disease progression | |
| 123269034 | 12326903 | Dry mouth | |
| 123269034 | 12326903 | Metastases to liver | |
| 123269034 | 12326903 | Nausea | |
| 123269034 | 12326903 | Pre-existing condition improved | |
| 123269034 | 12326903 | Renal neoplasm | |
| 123269034 | 12326903 | Therapeutic response unexpected |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123269034 | 12326903 | 2 | 2010 | 2014 | 0 | |
| 123269034 | 12326903 | 3 | 201507 | 0 | ||
| 123269034 | 12326903 | 4 | 2015 | 0 | ||
| 123269034 | 12326903 | 5 | 2010 | 2014 | 0 | |
| 123269034 | 12326903 | 6 | 2009 | 0 | ||
| 123269034 | 12326903 | 8 | 2014 | 0 |